Literature DB >> 16214088

Manipulation of immune regulation in systemic lupus erythematosus.

Antonio La Cava1, Celia J Fang, Ram P Singh, Fanny Ebling, Bevra H Hahn.   

Abstract

Production of autoantibodies by B cells in systemic lupus erythematosus (SLE) can be interrupted via induction of regulatory and suppressor T cells. We have used the strategy of tolerizing lupus-prone (NZBxNZW)F(1) mice with an artificial peptide based on sequences common to several anti-double stranded (ds)DNA antibodies to induce regulatory and suppressor T cells that block production of anti-DNA antibodies and prolong their survival. At least one type of suppressor T cells (CD8+) and one type of regulatory T cell (CD4+ expressing the IL-2 receptor alpha chain CD25) are raised under this condition. While CD8+ suppressors (TS) require soluble factors to block help of T cells to B cells, regulatory CD4+CD25+ T cells (TR) curb the production of anti-DNA antibodies from B cells via cell contact through molecules that include membrane-bound TGFbeta and GITR. Moreover, CD8+ suppressors seem to act independently on antigen specificity, while TR act in an antigen-specific fashion. We hypothesize that the differences between these two lymphocyte subsets that share the common ability to dampen production of autoantibodies might underlie significant temporal and teleological advantages for optimal control of autoimmune reactivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214088     DOI: 10.1016/j.autrev.2005.04.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  15 in total

Review 1.  T cells and B cells in lupus nephritis.

Authors:  Mary H Foster
Journal:  Semin Nephrol       Date:  2007-01       Impact factor: 5.299

2.  Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice.

Authors:  Xiaobin Tang; Bo Zhang; Justin A Jarrell; Jordan V Price; Hongjie Dai; Paul J Utz; Samuel Strober
Journal:  J Autoimmun       Date:  2014-02-07       Impact factor: 7.094

3.  CD5+ B lymphocytes in systemic lupus erythematosus patients: relation to disease activity.

Authors:  Hanan Hassan Omar; Samah Ismail Nasef; Hamdy Hassan Omar; Mona Sayed Ghaly
Journal:  Clin Rheumatol       Date:  2017-09-16       Impact factor: 2.980

4.  Subclinical hypothyroidism is a risk factor for delayed clinical complete response in patients with systemic lupus erythematosus (SLE).

Authors:  Lin Dong; Liu Jia; Xuezhi Hong; Guangliang Chen; Hanyou Mo
Journal:  Int J Clin Exp Med       Date:  2014-09-15

5.  Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.

Authors:  Lei Shen; Hong Zhang; Maria Caimol; Claudia J Benike; Eliza F Chakravarty; Samuel Strober; Edgar G Engleman
Journal:  Eur J Immunol       Date:  2014-11-27       Impact factor: 5.532

Review 6.  Regulation of autoimmune inflammation by pro-inflammatory cytokines.

Authors:  Eugene Y Kim; Kamal D Moudgil
Journal:  Immunol Lett       Date:  2008-08-09       Impact factor: 3.685

7.  Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus.

Authors:  Noriko Iikuni; Elaine V Lourenço; Bevra H Hahn; Antonio La Cava
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

Review 8.  IgM antibodies against dsDNA in SLE.

Authors:  Torsten Witte
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

9.  Regulatory T cells and their molecular markers in peripheral blood of the patients with systemic lupus erythematosus.

Authors:  Shaoxian Hu; Wenze Xiao; Fang Kong; Dan Ke; Ruifang Qin; Min Su
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.